Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Aurora A kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aurora Kinase (116) Adenosine Receptor (1) Akt (3) Aldehyde Dehydrogenase (ALDH) (1) Anaplastic lymphoma kinase (ALK) (3) Apoptosis (36) ASK1 (1) Autophagy (12) Bcr-Abl (10) c-Fms (1) c-Kit (2) c-Myc (1) CaMK (1) Caspase (2) CDK (5) DNA/RNA Synthesis (2) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (1) FAK (1) FGFR (5) FLT3 (11) G Protein-coupled Receptor Kinase (GRK) (2) Glycosidase (1) GSK-3 (1) HDAC (1) Histone Methyltransferase (1) HIV (1) IGF-1R (3) JAK (6) Kinesin (1) Ligands for Target Protein for PROTAC (3) LIM Kinase (LIMK) (1) LRRK2 (1) MASTL (2) MEK (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) Mitosis (6) MMP (1) NEKs (2) p38 MAPK (1) PARP (2) PDGFR (3) PERK (1) PKC (2) Polo-like Kinase (PLK) (2) PROTACs (8) Reactive Oxygen Species (ROS) (3) Reference Standards (8) ROCK (1) Ser/Thr Protease (1) Src (4) STAT (5) Syk (1) TAM Receptor (1) Tie (1) ULK (1) VEGFR (6)
By Research Areas:	Cancer (119) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (3)
Click Chemistry:	Alkynes (3)

130

Inhibitors & Agonists

Screening Libraries

Natural
Products

Click Chemistry

Targets Recommended: Aurora Kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10971

Alisertib Maximum Cited Publications 72 Publications Verification MLN 8237	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) is an orally active and selective **Aurora A kinase inhibitor (IC₅₀*=1.2 nM), which binds to Aurora* A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-10329

JNJ-7706621 5 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent **aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B**, respectively .

HY-10161

Tozasertib 15+ Cited Publications VX 680; MK-0457	Aurora Kinase Autophagy	Cancer
Tozasertib (VX 680; MK-0457) is an inhibitor of **Aurora A/B/C kinases with K_i**s of 0.6, 18, 4.6 nM, respectively.

HY-14711

Reversine 15+ Cited Publications	Aurora Kinase Autophagy	Cancer
Reversine is a novel class of ATP-competitive **Aurora kinase inhibitor with IC₅₀*s of 400, 500 and 400 nM for Aurora* A, Aurora B and Aurora C, respectively.

HY-10179

Danusertib 5+ Cited Publications PHA-739358	Aurora Kinase Autophagy	Cancer
Danusertib is a pyrrolo-pyrazole and **aurora kinase inhibitor with IC₅₀** of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-13253

AMG 900 4 Publications Verification	Aurora Kinase	Cancer
AMG 900 is a potent and highly selective *pan-Aurora* kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

HY-10180

MLN8054 5+ Cited Publications	Aurora Kinase	Cancer
MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC₅₀ of 4 nM.

HY-13252

MK-5108 5+ Cited Publications VX-689	Aurora Kinase Autophagy	Cancer
MK-5108 is a highly potent and specific inhibitor of **Aurora A kinase with an IC₅₀** value of 0.064 nM.

HY-10339

KW-2449 5+ Cited Publications	FLT3 FGFR Bcr-Abl Aurora Kinase Apoptosis	Cancer
KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL ^T315I and **Aurora kinase with IC₅₀**s of 6.6, 14, 4 and 48 nM, respectively.

HY-50514

AT9283 5+ Cited Publications	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, **Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀**=55 nM) .

HY-10128

ZM-447439 5+ Cited Publications	Aurora Kinase Apoptosis	Cancer
ZM-447439 is an *aurora* kinase inhibitor with IC₅₀s of 110 and 130 nM for aurora A and B, respectively.

HY-12003

SNS-314 mesylate 3 Publications Verification	Aurora Kinase	Cancer
SNS-314 mesylate is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-137377

TAS-119 1 Publications Verification	Aurora Kinase	Cancer
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC₅₀ of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC₅₀ of 95 nM). TAS-119 has potent antitumor activites .

HY-124526

Chiauranib Ibcasertib; CS2164	PDGFR c-Fms Aurora Kinase VEGFR c-Kit Mitosis	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀ values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

HY-156863

GRK2 Inhibitor 2 1 Publications Verification	Aurora Kinase G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GRK2 Inhibitor 2 is an orally active and selective G protein-coupled receptor kinase 2 (GRK) inhibitor with an IC₅₀ of 19 nM. GRK2 Inhibitor 2 also inhibits *Aurora-A* with an IC₅₀ of 137 nM. GRK2 Inhibitor 2 can be used in the study of congestive heart failure (HF) .

HY-112273

CD532 1 Publications Verification	Aurora Kinase	Cancer
CD532 is a potent **Aurora A kinase inhibitor with an IC₅₀** of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer .

HY-10804

CCT 137690 1 Publications Verification	Aurora Kinase Apoptosis	Cancer
CCT 137690 is a potent and orally available *aurora* kinase inhibitor with IC₅₀s of 15, 25, and 19 nM for aurora A, B and C, respectively.

HY-13819

MK-8745 4 Publications Verification	Aurora Kinase Apoptosis	Cancer
MK-8745 is an aurora A kinase inhibitor with an IC₅₀ of 0.6 nM.

HY-15749

XL228 4 Publications Verification	Aurora Kinase Bcr-Abl IGF-1R Src	Endocrinology Cancer
XL228 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.

HY-123159

AKI603	Aurora Kinase	Cancer
AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC₅₀ of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells .

HY-145601

Tinengotinib TT 00420	Aurora Kinase FGFR VEGFR	Cancer
Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC₅₀=1.2-3.3 nM), FGFR1/2/3 (IC₅₀=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual FLT3 and **Aurora kinase** inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-141512

JB170 3 Publications Verification	PROTACs Aurora Kinase	Cancer
JB170 is a potent and highly specific PROTAC-mediated *AURORA-A* (Aurora *Kinase) degrader (DC₅₀=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC₅₀=193 nM) over AURORA-B (EC₅₀=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase* .

HY-142817

GRK6/Aurora A-IN-1 3 Publications Verification	G Protein-coupled Receptor Kinase (GRK) Aurora Kinase	Cancer
GRK6/Aurora A-IN-1 is a dual inhibitor of G protein-coupled receptor kinase 6 (GRK6)/Aurora A, with IC₅₀ values of 120 nM and 11 nM, respectively. GRK6 is a key kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-2 has the potential for research on multiple myeloma .

HY-10178

PHA-680632	Aurora Kinase	Cancer
PHA-680632 is an *aurora* kinase inhibitor with IC₅₀s of 27, 135 and 120 nM for aurora A, B and C, respectively.

HY-122236

UMK57	Mitosis Kinesin Microtubule/Tubulin Aurora Kinase	Cancer
UMK57 is a MCAK activator and kinetochore-microtubule destabilizer. UMK57 enhances MCAK-dependent microtubule depolymerization, increases kinetochore-microtubule turnover, reduces chromosome mis-segregation and lagging chromosomes, and inhibits cancer cell proliferation. UMK57 triggers adaptive resistance in Aurora B cancer cells via reversible Aurora B signaling pathway alterations. UMK57 can be used for the research of solid tumors .

HY-151971

Aurora kinase-IN-3 1 Publications Verification	Aurora Kinase Polo-like Kinase (PLK)	Cancer
Aurora kinase-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10 .

HY-13072

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-125956

Aurkin A	Aurora Kinase Apoptosis	Cancer
Aurkin A is an allosteric inhibitor for the interaction between **Aurora A Kinase (also known also Aurka) and TPX2, through targeting the TPX2 binding sites with K_d of 3.77 μM. Aurkin A can disrupt polyploidy induced by Alisertib (HY-10971) and increase apoptosis** of tumor cells. Aurkin A can be used in research on mitosis and cancer .

HY-112355

Aurora kinase inhibitor-2	Aurora Kinase	Cancer
Aurora kinase inhibitor-2 is a selective and ATP-competitive **Aurora kinase inhibitor with IC₅₀*s of 310 nM and 240 nM for Aurora* A and Aurora B, respectively .

HY-112373

Aurora kinase inhibitor-3	Aurora Kinase	Others
Aurora kinase inhibitor-3 is a strong and selective **Aurora A kinase inhibitor with an IC₅₀** of 42 nM, and weakly inhibits EGFR with an IC₅₀ of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .

HY-12049

CCT129202	Aurora Kinase	Cancer
CCT129202 is an *aurora* kinase inhibitor with IC₅₀s of 42, 198, and 227 nM for aurora A, B and C, respectively.

HY-103266

TC-A 2317 hydrochloride	Aurora Kinase	Cancer
TC-A 2317 hydrochloride is an orally active **Aurora A kinase inhibitor (K_i*=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora* B kinase (K_i=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .

HY-112273A

CD532 hydrochloride 1 Publications Verification	Aurora Kinase	Cancer
CD532 hydrochloride is a potent **Aurora A kinase inhibitor with an IC₅₀** of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer .

HY-W231513

MASTL/Aurora A-IN-1	MASTL Ser/Thr Protease Aurora Kinase	Cancer
MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC₅₀ values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI₅₀ values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis .

HY-144991

Aurora kinase inhibitor-8	Aurora Kinase	Cancer
Aurora kinase inhibitor-8 is a highly selective inhibitor of the **Aurora kinases**.

HY-175866

Aurora kinase-IN-8	Aurora Kinase Apoptosis	Cancer
Aurora kinase-IN-8 is a orally active **Aurora kinase** inhibitor. Aurora kinase-IN-8 shows IC₅₀ values of 2.8 and 28.1 nM against **Aurora A kinase and Aurora B kinase*. Aurora* kinase-IN-8 can prevent spindle formation, cause G2/M phase arrest, and induce cell apoptosis. Aurora kinase-IN-8 can be used for the research of cancer, such as triple-negative breast cancer .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective *spleen tyrosine kinase* (SYK) inhibitor with a pIC₅₀** of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-175830

PROTAC AURKA degrader 1	PROTACs Aurora Kinase	Cancer
PROTAC AURKA degrader 1 (Compound A16 + X7) is a Aurora kinase A (AURKA) PROTAC degrader. PROTAC AURKA degrader 1 can be used for cancers research . Pink: AURKA ligand (HY-175827); Blue: CRBN ligase ligand (HY-W867704); Black: linker (HY-132208)

HY-123610

BRD-7880	Aurora Kinase	Cancer
BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC₅₀ values of 7 nM and 12 nM, respectively .

HY-175526

Aurora kinase ligand-1	Ligands for Target Protein for PROTAC Aurora Kinase	Cancer
Aurora kinase ligand-1 (Compound I-4) is an Aurora kinase B (AURKB) PROTAC ligand. Aurora kinase ligand-1 can be conjugated with E3 ligase Ligand (HY-112078) and linker to synthesize AURKB PROTAC degrader MS44 (HY-175525). MS44 can be used for cancer research .

HY-108344

SNS-314	Aurora Kinase	Cancer
SNS-314 is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-10971A

Alisertib sodium MLN 8237 sodium	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) sodium is an orally active and selective **Aurora A kinase inhibitor (IC₅₀*=1.2 nM), which binds to Aurora* A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-175827

MK-5108-NH-PEG2-alkyne	Aurora Kinase Ligands for Target Protein for PROTAC	Cancer
MK-5108-NH-PEG2-alkyne is a Aurora kinase A (AURKA) inhibitor. MK-5108-NH-PEG2-alkyne can be used for synthesis of PROTAC AURKA degrader 1 (HY-175830) .

HY-149693

Aurora kinase inhibitor-11	Aurora Kinase	Cancer
Aurora kinase inhibitor-11 (compound 25) is an inhibitor of Aurora Kinase with an IC₅₀ of 0.14 μM. Aurora kinase inhibitor-11 has anticancer activity .

HY-158618

Aurora kinase inhibitor-14	Aurora Kinase Apoptosis	Cancer
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of **Aurora kinases with IC₅₀** values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .

HY-147703

Aurora kinase inhibitor-9	Aurora Kinase	Cancer
Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC₅₀s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .

HY-111506

Aurora inhibitor 1	Aurora Kinase	Cancer
Aurora inhibitor 1 is a potent *Aurora* inhibitor with an IC₅₀ of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively .

HY-122370A

Tripolin B	Aurora Kinase	Cancer
Tripolin B is an ATP-competitive **Aurora kinase inhibitor with IC₅₀** values of 2.5 µM and 6 µM for Aurora A and Aurora B kinases, respectively. Tripolin B does not inhibit Aurora kinase in cells .

Cat. No.	Product Name

HY-L004

Cell Cycle/DNA Damage Compound Library

3,313 compounds

DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.

MCE owns a unique collection of 3,313 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cat. No.	Product Name		Classification

HY-116423

JH295		Alkynes
JH295 is a potent, irreversible and selective *NIMA-related kinase* 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2** via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-175827

MK-5108-NH-PEG2-alkyne		Alkynes
MK-5108-NH-PEG2-alkyne is a Aurora kinase A (AURKA) inhibitor. MK-5108-NH-PEG2-alkyne can be used for synthesis of PROTAC AURKA degrader 1 (HY-175830) .

HY-116423A

JH295 hydrate		Alkynes
JH295 hydrate is a potent, irreversible and selective *NIMA-related kinase* 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2** via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks